$CLNN
Clene Inc. Stock $clnn

$clnn Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000143774924034663 Filed on November 13, 2024

Income Statement

Concept	2024 Q4	2024 Q3
Revenue		$87.00K
YoY Change		-19.44%
Cost Of Revenue		$18.00K
YoY Change		50.0%
Gross Profit		$69.00K
YoY Change		-28.13%
Gross Profit Margin		79.31%
Selling, General & Admin		$3.346M
YoY Change		-7.06%
% of Gross Profit		4849.28%
Research & Development		$4.471M
YoY Change		-25.13%
% of Gross Profit		6479.71%
Depreciation & Amortization		$406.0K
YoY Change		-7.52%
% of Gross Profit		588.41%
Operating Expenses		$4.471M
YoY Change		-25.13%
Operating Profit		-$7.800M
YoY Change		-18.26%
Interest Expense		-$895.0K
YoY Change		-175.34%
% of Operating Profit
Other Income/Expense, Net		-$171.0K
YoY Change		-102.4%
Pretax Income		-$7.986M
YoY Change		230.27%
Income Tax		$0.00
% Of Pretax Income
Net Earnings		-$7.986M
YoY Change		230.27%
Net Earnings / Revenue		-9179.31%
Basic Earnings Per Share		-$1.22
Diluted Earnings Per Share		-$1.22
COMMON SHARES
Basic Shares Outstanding	7.980M	6.470M
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q4	2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments		$14.65M
YoY Change		-65.22%
Cash & Equivalents		$14.65M
Short-Term Investments		$0.00
Other Short-Term Assets		$777.0K
YoY Change		-24.49%
Inventory		$128.0K
Prepaid Expenses
Receivables		$0.00
Other Receivables		$351.0K
Total Short-Term Assets		$19.70M
YoY Change		-57.59%
LONG-TERM ASSETS
Property, Plant & Equipment		$11.81M
YoY Change		-15.2%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets		$58.00K
YoY Change		-3.33%
Total Long-Term Assets		$11.87M
YoY Change		-15.13%
TOTAL ASSETS
Total Short-Term Assets		$19.70M
Total Long-Term Assets		$11.87M
Total Assets		$31.57M
YoY Change		-47.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$1.678M
YoY Change		-11.17%
Accrued Expenses		$6.733M
YoY Change		110.8%
Deferred Revenue
YoY Change
Short-Term Debt		$0.00
YoY Change
Long-Term Debt Due		$10.88M
YoY Change		12.93%
Total Short-Term Liabilities		$23.83M
YoY Change		56.06%
LONG-TERM LIABILITIES
Long-Term Debt		$6.939M
YoY Change		-58.32%
Other Long-Term Liabilities		$4.927M
YoY Change		-30.7%
Total Long-Term Liabilities		$11.87M
YoY Change		-50.06%
TOTAL LIABILITIES
Total Short-Term Liabilities		$23.83M
Total Long-Term Liabilities		$11.87M
Total Liabilities		$35.69M
YoY Change		-8.54%
SHAREHOLDERS EQUITY
Retained Earnings		-$268.6M
YoY Change		15.48%
Common Stock		$1.000K
YoY Change		-92.31%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		-$4.125M
YoY Change
Total Liabilities & Shareholders Equity		$31.57M
YoY Change		-47.76%

Cashflow Statement

Concept	2024 Q4	2024 Q3
OPERATING ACTIVITIES
Net Income		-$7.986M
YoY Change		230.27%
Depreciation, Depletion And Amortization		$406.0K
YoY Change		-7.52%
Cash From Operating Activities		-$3.023M
YoY Change		-55.28%
INVESTING ACTIVITIES
Capital Expenditures		$1.000K
YoY Change		-98.0%
Acquisitions
YoY Change
Other Investing Activities		$0.00
YoY Change
Cash From Investing Activities		-$1.000K
YoY Change		-98.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		-4.066M
YoY Change		1594.17%
NET CHANGE
Cash From Operating Activities		-3.023M
Cash From Investing Activities		-1.000K
Cash From Financing Activities		-4.066M
Net Change In Cash		-7.090M
YoY Change		0.57%
FREE CASH FLOW
Cash From Operating Activities		-$3.023M
Capital Expenditures		$1.000K
Free Cash Flow		-$3.024M
YoY Change		-55.59%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001822791
	dei	Entity Registrant Name EntityRegistrantName	Clene Inc.
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-46000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-212000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-131000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-723000	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7986000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2418000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-25851000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-39331000	usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	600000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6857170
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6857170
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6421084
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6421084
CY2024Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2024Q3	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	12000	usd
CY2024Q3	us-gaap	Lease Cost LeaseCost	355000	usd
CY2024Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	0	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6857170
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6421084
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	01-39834
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-2828339
	dei	Entity Address Address Line1 EntityAddressAddressLine1	6550 South Millrock Drive, Suite G50
	dei	Entity Address City Or Town EntityAddressCityOrTown	Salt Lake City
	dei	Entity Address State Or Province EntityAddressStateOrProvince	UT
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	84121
	dei	City Area Code CityAreaCode	801
	dei	Local Phone Number LocalPhoneNumber	676-9695
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	7979726
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14645000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28821000	usd
CY2024Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	0	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	6179000	usd
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	143000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	128000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	37000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4925000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3672000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	19698000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	38852000	usd
CY2024Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	58000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	58000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3776000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4168000	usd
CY2024Q3	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	8037000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	9263000	usd
CY2024Q3	us-gaap	Assets Assets	31569000	usd
CY2023Q4	us-gaap	Assets Assets	52341000	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1678000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1504000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6733000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3720000	usd
CY2024Q3	clnn	Share Subscriptions Payable ShareSubscriptionsPayable	3810000	usd
CY2023Q4	clnn	Share Subscriptions Payable ShareSubscriptionsPayable	0	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	732000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	576000	usd
CY2024Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	0	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	27000	usd
CY2024Q3	us-gaap	Notes Payable Current NotesPayableCurrent	10875000	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	14627000	usd
CY2024Q3	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	0	usd
CY2023Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	4876000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	23828000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	25330000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4335000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4903000	usd
CY2024Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	1668000	usd
CY2023Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	1894000	usd
CY2024Q3	clnn	Convertible Note Payable Noncurrent ConvertibleNotePayableNoncurrent	5271000	usd
CY2023Q4	clnn	Convertible Note Payable Noncurrent ConvertibleNotePayableNoncurrent	5258000	usd
CY2024Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	592000	usd
CY2023Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1481000	usd
CY2024Q3	clnn	Clene Nanomedicine Contingent Earnout CleneNanomedicineContingentEarnout	0	usd
CY2023Q4	clnn	Clene Nanomedicine Contingent Earnout CleneNanomedicineContingentEarnout	75000	usd
CY2024Q3	clnn	Initial Shareholders Contingent Earnout InitialShareholdersContingentEarnout	0	usd
CY2023Q4	clnn	Initial Shareholders Contingent Earnout InitialShareholdersContingentEarnout	10000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	35694000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	38951000	usd
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	264225000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	255913000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-268574000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-242723000	usd
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	223000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	199000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-4125000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	13390000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	31569000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	52341000	usd
CY2024Q3	us-gaap	Revenues Revenues	87000	usd
CY2023Q3	us-gaap	Revenues Revenues	108000	usd
	us-gaap	Revenues Revenues	251000	usd
	us-gaap	Revenues Revenues	484000	usd
CY2024Q3	us-gaap	Cost Of Revenue CostOfRevenue	18000	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	12000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	52000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	83000	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4471000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5972000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14490000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19982000	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3413000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3666000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10147000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11029000	usd
CY2024Q3	us-gaap	Costs And Expenses CostsAndExpenses	7902000	usd
CY2023Q3	us-gaap	Costs And Expenses CostsAndExpenses	9650000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	24689000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	31094000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-7815000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-9542000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-24438000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-30610000	usd
CY2024Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	127000	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	546000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	755000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	931000	usd
CY2024Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	1022000	usd
CY2023Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	1188000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	3548000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	3358000	usd
CY2024Q3	clnn	Purchase Agreement Commitment Share Expense PurchaseAgreementCommitmentShareExpense	-0	usd
CY2023Q3	clnn	Purchase Agreement Commitment Share Expense PurchaseAgreementCommitmentShareExpense	-0	usd
	clnn	Purchase Agreement Commitment Share Expense PurchaseAgreementCommitmentShareExpense	-0	usd
	clnn	Purchase Agreement Commitment Share Expense PurchaseAgreementCommitmentShareExpense	402000	usd
CY2024Q3	clnn	Issuance Costs For Common Stock Warrant Liability IssuanceCostsForCommonStockWarrantLiability	-0	usd
CY2023Q3	clnn	Issuance Costs For Common Stock Warrant Liability IssuanceCostsForCommonStockWarrantLiability	-0	usd
	clnn	Issuance Costs For Common Stock Warrant Liability IssuanceCostsForCommonStockWarrantLiability	-0	usd
	clnn	Issuance Costs For Common Stock Warrant Liability IssuanceCostsForCommonStockWarrantLiability	333000	usd
CY2024Q3	clnn	Gain Loss On Issuance Of Equity GainLossOnIssuanceOfEquity	0	usd
CY2023Q3	clnn	Gain Loss On Issuance Of Equity GainLossOnIssuanceOfEquity	0	usd
	clnn	Gain Loss On Issuance Of Equity GainLossOnIssuanceOfEquity	0	usd
	clnn	Gain Loss On Issuance Of Equity GainLossOnIssuanceOfEquity	-14840000	usd
CY2024Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-697000	usd
CY2023Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-6341000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-956000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-5958000	usd
CY2024Q3	clnn	Change In Fair Value Of Contingent Earnout ChangeInFairValueOfContingentEarnout	0	usd
CY2023Q3	clnn	Change In Fair Value Of Contingent Earnout ChangeInFairValueOfContingentEarnout	1004000	usd
	clnn	Change In Fair Value Of Contingent Earnout ChangeInFairValueOfContingentEarnout	75000	usd
	clnn	Change In Fair Value Of Contingent Earnout ChangeInFairValueOfContingentEarnout	2114000	usd
CY2024Q3	clnn	Change In Fair Value Of Initial Shareholders Contingent Earnout ChangeInFairValueOfInitialShareholdersContingentEarnout	0	usd
CY2023Q3	clnn	Change In Fair Value Of Initial Shareholders Contingent Earnout ChangeInFairValueOfInitialShareholdersContingentEarnout	129000	usd
	clnn	Change In Fair Value Of Initial Shareholders Contingent Earnout ChangeInFairValueOfInitialShareholdersContingentEarnout	10000	usd
	clnn	Change In Fair Value Of Initial Shareholders Contingent Earnout ChangeInFairValueOfInitialShareholdersContingentEarnout	272000	usd
CY2024Q3	us-gaap	Government Assistance Amount GovernmentAssistanceAmount	27000	usd
CY2023Q3	us-gaap	Government Assistance Amount GovernmentAssistanceAmount	247000	usd
	us-gaap	Government Assistance Amount GovernmentAssistanceAmount	339000	usd
	us-gaap	Government Assistance Amount GovernmentAssistanceAmount	902000	usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	45000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	35000	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-171000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	7124000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1413000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-8721000	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7986000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2418000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-25851000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-39331000	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-7986000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2418000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-25851000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-39331000	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	1000	usd
CY2023Q3	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	-4000	usd
	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	-1000	usd
	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	16000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	52000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-81000	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	25000	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-130000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	53000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-85000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	24000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-114000	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7933000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2503000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-25827000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-39445000	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.22
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.38
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-8.11
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6557839
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6420274
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6467771
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4851348
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	13390000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2013000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2024Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-4000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-55000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-11080000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	4264000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	36000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1951000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	2000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	28000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-6785000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-504000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2036000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	88000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2188000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	52000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-7986000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-4125000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	3237000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4664000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2223000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	14000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	4000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-11770000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-1628000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	40924000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	4970000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2451000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2023Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	6000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-53000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-25143000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	21527000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	20000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2396000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2023Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-4000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-81000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2418000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	21400000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-25851000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-39331000	usd
	us-gaap	Depreciation Depreciation	1240000	usd
	us-gaap	Depreciation Depreciation	1283000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	394000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	315000	usd
	clnn	Purchase Agreement Commitment Share Expense PurchaseAgreementCommitmentShareExpense	0	usd
	clnn	Purchase Agreement Commitment Share Expense PurchaseAgreementCommitmentShareExpense	402000	usd
	clnn	Issuance Costs For Common Stock Warrant Liability IssuanceCostsForCommonStockWarrantLiability	0	usd
	clnn	Issuance Costs For Common Stock Warrant Liability IssuanceCostsForCommonStockWarrantLiability	333000	usd
	clnn	Gain Loss On Issuance Of Equity GainLossOnIssuanceOfEquity	-0	usd
	clnn	Gain Loss On Issuance Of Equity GainLossOnIssuanceOfEquity	-14840000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-956000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-5958000	usd
	clnn	Change In Fair Value Of Contingent Earnout ChangeInFairValueOfContingentEarnout	75000	usd
	clnn	Change In Fair Value Of Contingent Earnout ChangeInFairValueOfContingentEarnout	2114000	usd
	clnn	Change In Fair Value Of Initial Shareholders Contingent Earnout ChangeInFairValueOfInitialShareholdersContingentEarnout	10000	usd
	clnn	Change In Fair Value Of Initial Shareholders Contingent Earnout ChangeInFairValueOfInitialShareholdersContingentEarnout	272000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	6152000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	7070000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1184000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	819000	usd
	clnn	Noncash Interest Income Expense On Marketable Securities NoncashInterestIncomeExpenseOnMarketableSecurities	153000	usd
	clnn	Noncash Interest Income Expense On Marketable Securities NoncashInterestIncomeExpenseOnMarketableSecurities	-0	usd
	clnn	Noncash Interest Income Expense On Notes Payable NoncashInterestIncomeExpenseOnNotesPayable	-40000	usd
	clnn	Noncash Interest Income Expense On Notes Payable NoncashInterestIncomeExpenseOnNotesPayable	-273000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-143000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-125000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	91000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	61000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1185000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1483000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	174000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1125000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2945000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-669000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-412000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-412000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16461000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22999000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	6168000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	-0	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	12500000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	5000000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	287000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	6318000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	4713000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	124000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
	clnn	Proceeds From Issuance Of Common Stock And Warrants Net Of Offering Costs ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfOfferingCosts	2036000	usd
	clnn	Proceeds From Issuance Of Common Stock And Warrants Net Of Offering Costs ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfOfferingCosts	42094000	usd
	clnn	Proceeds From Share Subscriptions Payable ProceedsFromShareSubscriptionsPayable	3810000	usd
	clnn	Proceeds From Share Subscriptions Payable ProceedsFromShareSubscriptionsPayable	0	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	27000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	63000	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	350000	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	10000000	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	-0	usd
	us-gaap	Payments Of Debt Restructuring Costs PaymentsOfDebtRestructuringCosts	-0	usd
	us-gaap	Payments Of Debt Restructuring Costs PaymentsOfDebtRestructuringCosts	200000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-4057000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	42181000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	24000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-114000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-14176000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	23781000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	28879000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	18390000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	14703000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	42171000	usd
CY2024Q3	us-gaap	Cash Cash	14645000	usd
CY2023Q3	us-gaap	Cash Cash	42113000	usd
CY2024Q3	us-gaap	Restricted Cash RestrictedCash	58000	usd
CY2023Q3	us-gaap	Restricted Cash RestrictedCash	58000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14703000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	42171000	usd
	clnn	Common Stock Warrant Liability Recorded Upon Debt Modification CommonStockWarrantLiabilityRecordedUponDebtModification	67000	usd
	clnn	Common Stock Warrant Liability Recorded Upon Debt Modification CommonStockWarrantLiabilityRecordedUponDebtModification	692000	usd
	clnn	Common Stock Warrant Liability Recorded Upon Public Stock Offering CommonStockWarrantLiabilityRecordedUponPublicStockOffering	0	usd
	clnn	Common Stock Warrant Liability Recorded Upon Public Stock Offering CommonStockWarrantLiabilityRecordedUponPublicStockOffering	7126000	usd
	clnn	Deferred Transaction Costs In Accrued Liabilities And Other Current Assets DeferredTransactionCostsInAccruedLiabilitiesAndOtherCurrentAssets	68000	usd
	clnn	Deferred Transaction Costs In Accrued Liabilities And Other Current Assets DeferredTransactionCostsInAccruedLiabilitiesAndOtherCurrentAssets	0	usd
	us-gaap	Interest Paid Net InterestPaidNet	2324000	usd
	us-gaap	Interest Paid Net InterestPaidNet	2266000	usd
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-7800000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-9500000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-24400000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-30600000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-268600000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-242700000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	14600000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	35000000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16500000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23000000	usd
	clnn	Minimum Cash Balance For Loan Covenant MinimumCashBalanceForLoanCovenant	5000000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and disclosure of contingent assets and liabilities, and the reported amounts of expenses. We base our estimates on historical experience and various other assumptions that we believe to be reasonable. Actual results <em style="font: inherit;"> may </em>differ from those estimates or assumptions. Estimates are periodically reviewed in light of changes in circumstances, facts, and experience, and any changes in estimates will be recorded in future periods as they develop.</p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Concentrations of Credit Risk</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt;">Financial instruments which potentially subject us to significant concentrations of credit risk consist primarily of cash. Our cash is held in financial institutions and amounts on deposit <em style="font: inherit;"> may </em>at times exceed federally insured limits. We have <em style="font: inherit;">not</em> experienced any losses on our deposits of cash and do <em style="font: inherit;">not</em> believe that we are subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
CY2024Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	114000	usd
CY2024Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	14000	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	23000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	14000	usd
CY2024Q3	clnn	Prepaid Clinical And Cro Expenses PrepaidClinicalAndCroExpenses	2053000	usd
CY2023Q4	clnn	Prepaid Clinical And Cro Expenses PrepaidClinicalAndCroExpenses	0	usd
CY2024Q3	us-gaap	Supplies Supplies	1744000	usd
CY2023Q4	us-gaap	Supplies Supplies	1909000	usd
CY2024Q3	us-gaap	Government Assistance Amount Cumulative GovernmentAssistanceAmountCumulative	351000	usd
CY2023Q4	us-gaap	Government Assistance Amount Cumulative GovernmentAssistanceAmountCumulative	1195000	usd
CY2024Q3	us-gaap	Other Assets Current OtherAssetsCurrent	777000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	568000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4925000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3672000	usd
CY2024Q3	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	15509000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	16150000	usd
CY2024Q3	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	7472000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	6887000	usd
CY2024Q3	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	8037000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	9263000	usd
CY2024Q3	us-gaap	Depreciation Depreciation	406000	usd
CY2023Q3	us-gaap	Depreciation Depreciation	439000	usd
	us-gaap	Depreciation Depreciation	1240000	usd
	us-gaap	Depreciation Depreciation	1283000	usd
CY2024Q3	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	3691000	usd
CY2023Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	2120000	usd
CY2024Q3	us-gaap	Government Assistance Liability Current GovernmentAssistanceLiabilityCurrent	2060000	usd
CY2023Q4	us-gaap	Government Assistance Liability Current GovernmentAssistanceLiabilityCurrent	438000	usd
CY2024Q3	clnn	Accrued Cro And Clinical Fees AccruedCroAndClinicalFees	804000	usd
CY2023Q4	clnn	Accrued Cro And Clinical Fees AccruedCroAndClinicalFees	481000	usd
CY2024Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	178000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	681000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6733000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3720000	usd
CY2024Q2	clnn	Number Of Real Estate Leases NumberOfRealEstateLeases	3	pure
CY2024Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.096	pure
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.096	pure
CY2024Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y8M12D
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y4M24D
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	449000	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	187000	usd
CY2023Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.11	pure
CY2023Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P0Y4M24D
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	48000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1458000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1236000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1132000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1093000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	649000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	1045000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	6661000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1594000	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	5067000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	732000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4335000	usd
CY2023Q3	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	16000	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	57000	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	57000	usd
CY2024Q3	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	0	usd
CY2023Q3	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1000	usd
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	0	usd
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	10000	usd
CY2024Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	255000	usd
CY2023Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	254000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	764000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	758000	usd
CY2024Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	usd
CY2023Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	1000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	2000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	3000	usd
CY2024Q3	us-gaap	Variable Lease Cost VariableLeaseCost	88000	usd
CY2023Q3	us-gaap	Variable Lease Cost VariableLeaseCost	70000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	217000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	192000	usd
CY2023Q3	us-gaap	Lease Cost LeaseCost	342000	usd
	us-gaap	Lease Cost LeaseCost	1040000	usd
	us-gaap	Lease Cost LeaseCost	1020000	usd
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2188000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2396000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6152000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7070000	usd
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2188000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2396000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6152000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7070000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1092343
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	45.2
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M10D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	302000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	918849
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.04
	clnn	Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants In Period Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm	P9Y8M19D
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	41090
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	65000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	12288
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	88.26
	us-gaap	Operating Lease Payments OperatingLeasePayments	983000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	953000	usd
	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	-0	usd
	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	10000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	27000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	63000	usd
CY2024Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	11951000	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	16915000	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-7940000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-2206000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-25720000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-38608000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	61770
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1896044
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	28.76
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y5M4D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	728239
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	51.48
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y18D
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1896044
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	28.76
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P8Y5M4D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	0	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.09
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	15
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	543
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	23
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	959
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	196.84
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	11000	usd
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P0Y2M23D
CY2023Q4	clnn	Clene Nanomedicine Contingent Earnout Fair Value Disclosure CleneNanomedicineContingentEarnoutFairValueDisclosure	75000	usd
CY2023Q4	clnn	Initial Shareholders Contingent Earnout Fair Value Disclosure InitialShareholdersContingentEarnoutFairValueDisclosure	10000	usd
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	600000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6857170
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6421084
CY2024Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	5271604
CY2023Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	5271604
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-7986000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2418000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-25851000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-39331000	usd
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6557839
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6420274
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6467771
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4851348
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.22
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.38
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-8.11
CY2024Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7597217
CY2023Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6801671
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7597217
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6801671
CY2018Q3	clnn	Related Party Transaction Royalty Fee Rate For Revenues RelatedPartyTransactionRoyaltyFeeRateForRevenues	0.03	pure

Files In Submission

Name	View Source	Status
0001437749-24-034663-index-headers.html	Edgar Link	pending
0001437749-24-034663-index.html	Edgar Link	pending
0001437749-24-034663.txt	Edgar Link	pending
0001437749-24-034663-xbrl.zip	Edgar Link	pending
clnn-20240930.xsd	Edgar Link	pending
clnn20240930_10q.htm	Edgar Link	pending
ex_714261.htm	Edgar Link	pending
ex_714262.htm	Edgar Link	pending
ex_714263.htm	Edgar Link	pending
ex_714264.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pipelineoct202423pct.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
clnn-20240930_def.xml	Edgar Link	unprocessable
clnn-20240930_lab.xml	Edgar Link	unprocessable
clnn-20240930_pre.xml	Edgar Link	unprocessable
clnn20240930_10q_htm.xml	Edgar Link	completed
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
clnn-20240930_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CLNN
Clene Inc. Stock $clnn

2024 Q4 Form 10-Q Financial Statement

#000143774924034663 Filed on November 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLNN Clene Inc. Stock $clnn

2024 Q4 Form 10-Q Financial Statement

#000143774924034663 Filed on November 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLNN
Clene Inc. Stock $clnn